Use of Blood-Based Biomarkers for Early Diagnosis and Surveillance of Colorectal Cancer

World Journal of Gastrointestinal Oncology

Volumn 6, Issue 4, 2014, Pages 83-97

  Ganepola, Ganepola AP ^a,b   Nizin, Joel ^a,b   Rutledge, John R ^a   Chang, David H ^a  

^a Daniel and Gloria Blumenthal Cancer Center   (United States)

^b VALLEY HOSPITAL   (United States)

Author keywords

Biological markers; Blood; Colonoscopy; Colorectal neoplasms; Early detection of cancer; DNA; High throughput nucleotide sequencing; Long non coding RNA; Loss of heterozygosity; Mass; Messenger; methylation; Microarray analysis; MicroRNA; Microsatellite instability; Real time polymerase chain reaction; RNA; spectrometry

Indexed keywords

EID: 84902543626     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i4.83     Document Type: Article

References (166)

1. 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO- CAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. 2 Pourhoseingholi MA. Increased burden of colorectal can¬cer in Asia. World J Gastrointest Oncol 2012; 4: 68-70 [PMID: 22532878 DOI: 10.4251/wjgo.v4.i4.68]
3. 3 Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012; 13: 790-801 [PMID: 22658655 DOI: 10.1016/S1470-2045(12)70211-5]
4. 4 Population Division. World Population Prospects: The 2012 Revision, Highlights and Advance Tables. New York: United Nations Department of Economic and Social Affairs, 2013
5. 5 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276 [PMID: 9142060 DOI: 10.1016/S0140-6736(96) 07493-4]
6. 6 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/ caac.21166]
7. 7 Eddy D. ACS report on the cancer-related health checkup. CA Cancer J Clin 1980; 30: 193-240 [PMID: 6774802]
8. 8 Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiol¬ogy. CA Cancer J Clin 2008; 58: 130-160 [PMID: 18322143 DOI: 10.3322/CA.2007.0018]
9. 9 U.S. Preventive Services Task Force. Screening for colorec¬tal cancer: recommendation and rationale. Am Fam Physician 2002; 66: 2287-2290 [PMID: 12507168]
10. 10 Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thor- son A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-1885 [PMID: 16697750 DOI: 10.1053/j.gas- tro.2006.03.012]
11. 11 Diaz JA, Slomka T. State of the Art Review: Colorectal Can¬cer Screening. Am J Lifestyle Med 2012; 6: 196-203 [PMID: 23539676 DOI: 10.1177/1559827611413243]
12. 12 Steinwachs D, Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P, Lave JR, Laveist TA, Ness RB, Optican RJ, Virnig BA. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010; 152: 663-667 [PMID: 20388702 DOI: 10.7326/0003-4819-152-1 0-201005180-00237]
13. 13 Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 2006; 7: 127-131 [PMID: 16455476 DOI: 10.1016/S1470-2045(0 5)70473-3]
14. 14 Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Co¬chrane systematic review of colorectal cancer screening us¬ing the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549 [PMID: 18479499 DOI: 10.1111/j.1572-0241.2008.01875.x]
15. 15 Health Quality Ontario. Fecal occult blood test for colorec¬tal cancer screening: an evidence-based analysis. Ont Health Technol Assess Ser 2009; 9: 1-40 [PMID: 23074514]
16. 16 Schnell T, Aranha GV, Sontag SJ, Tode R, Reid S, Chejfec G, Karpf J, Levine G. Fecal occult blood testing: a false sense of security? Surgery 1994; 116: 798-802; discussion 802-803 [PMID: 7940181]
17. 17 Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detec¬tion of advanced colonic adenomas and cancer. Int J Colorec¬tal Dis 2012; 27: 1657-1664 [PMID: 22696204 DOI: 10.1007/ s00384-012-1518-3]
18. 18 Roslani AC, Abdullah T, Arumugam K. Screening for colorec¬tal neoplasias with fecal occult blood tests: false-positive im¬pact of non-dietary restriction. Asian Pac J Cancer Prev 2012; 13: 237-241 [PMID: 22502676]
19. 19 Mant D, Fitzpatrick R, Hogg A, Fuller A, Farmer A, Verne J, Northover J. Experiences of patients with false positive results from colorectal cancer screening. Br J Gen Pract 1990; 40: 423-425 [PMID: 2271264]
20. 20 Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A compari¬son of fecal occult-blood tests for colorectal-cancer screen¬ing. N Engl J Med 1996; 334: 155-159 [PMID: 8531970 DOI: 10.1056/NEJM199601183340304]
21. 21 Heresbach D, Manfredi S, D'halluin PN, Bretagne JF, Brang- er B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006; 18: 427-433 [PMID: 16538116]
22. 22 Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104: 739-750 [PMID: 19240699 DOI: 10.1038/ajg.2009.104]
23. 23 Meissner HI, Breen N, Klabunde CN, Vernon SW. Pat¬terns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15: 389-394 [PMID: 16492934 DOI: 10.1158/1055-9965. EPI-05-0678]
24. 24 Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control 2008; 19: 339-359 [PMID: 18085415 DOI: 10.1007/s10552-007-9100-y]
25. 25 Ait Ouakrim D, Lockett T, Boussioutas A, Hopper JL, Jen¬kins MA. Screening participation for people at increased risk of colorectal cancer due to family history: a systematic re¬view and meta-analysis. Fam Cancer 2013; 12: 459-472 [PMID: 23700069 DOI: 10.1007/s10689-013-9658-3]
26. 26 Cummings LC, Cooper GS. Colorectal cancer screening: up¬date for 2011. Semin Oncol 2011; 38: 483-489 [PMID: 21810507 DOI: 10.1053/j.seminoncol.2011.05.002]
27. 27 Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physi¬cian counseling. Prev Med 2005; 41: 23-29 [PMID: 15916989 DOI: 10.1016/j.ypmed.2004.11.004]
28. 28 Boehm JE, Rohan EA, Preissle J, DeGroff A, Glover-Kudon R. Recruiting patients into the CDC's Colorectal Cancer Screen¬ing Demonstration Program: strategies and challenges across 5 sites. Cancer 2013; 119 Suppl 15: 2914-2925 [PMID: 23868486 DOI: 10.1002/ cncr.28161]
29. 29 Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitudes toward colorectal cancer screening tests. J Gen In¬tern Med 2001; 16: 822-830 [PMID: 11903761]
30. 30 Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P. Colorectal cancer screening in Europe. World J Gas¬troenterol 2009; 15: 5907-5915 [PMID: 20014454]
31. 31 Sieg A, Friedrich K. Perspectives of colorectal cancer screen¬ing in Germany 2009. World J Gastrointest Endosc 2009; 1: 12-16 [PMID: 21160645 DOI: 10.4253/wjge.v1.i1.12]
32. 32 Deng SX, Gao J, An W, Yin J, Cai QC, Yang H, Li ZS. Colorectal cancer screening behavior and willingness: an outpatient survey in China. World J Gastroenterol 2011; 17: 3133-3139 [PMID: 21912456 DOI: 10.3748/wjg.v17.i26.3133]
33. 33 Levin TR, Corley DA. Colorectal-cancer screening––coming of age. N Engl J Med 2013; 369: 1164-1166 [PMID: 24047066 DOI: 10.1056/NEJMe1308253]
34. 34 Steele SR, Johnson EK, Champagne B, Davis B, Lee S, Rivad- eneira D, Ross H, Hayden DA, Maykel JA. Endoscopy and polyps-diagnostic and therapeutic advances in management. World J Gastroenterol 2013; 19: 4277-4288 [PMID: 23885138 DOI: 10.3748/wjg.v19.i27.4277]
35. 35 Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effec¬tiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 1954-1961 [PMID: 11035892]
36. 36 Sonnenberg A, Delcò F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 573-584 [PMID: 11033584]
37. 37 Tsoi KK, Ng SS, Leung MC, Sung JJ. Cost-effectiveness anal¬ysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther 2008; 28: 353-363 [PMID: 18638075 DOI: 10.1111/j.1365-2036.2008.0372 6.x]
38. 38 Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorec¬tal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010; 7: e1000370 [PMID: 21124887 DOI: 10.1371/journal.pmed.1000370]
39. 39 Debey-Pascher S, Chen J, Voss T, Staratschek-Jox A. Blood- based miRNA preparation for noninvasive biomarker devel¬opment. Methods Mol Biol 2012; 822: 307-338 [PMID: 22144209 DOI: 10.1007/978-1-61779-427-8_22]
40. 40 Kumar S, Mohan A, Guleria R. Biomarkers in cancer screen¬ing, research and detection: present and future: a review. Biomarkers 2006; 11: 385-405 [PMID: 16966157 DOI: 10.1080/1 3547500600775011]
41. 41 Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005; 1: 37-50 [PMID: 16555974 DOI: 10.1517/14796694.1.1.37]
42. 42 Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharma¬col Ther 2013; 140: 133-147 [PMID: 23791941 DOI: 10.1016/ j.pharmthera.2013.06.005]
43. 43 Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007; 13: 6719-6726 [PMID: 18006773 DOI: 10.1158/1078-0432.CCR-06-2860]
44. 44 Zeestraten EC, Kuppen PJ, van de Velde CJ, Marijnen CA. Prediction in rectal cancer. Semin Radiat Oncol 2012; 22: 175-183 [PMID: 22385923 DOI: 10.1016/j.semradonc.2011.12.005]
45. 45 Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP. Analysis of cell-free Epstein- Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem 1999; 45: 1292-1294 [PMID: 10430801]
46. 46 Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002; 48: 1647-1653 [PMID: 12324479]
47. 47 Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with ma¬lignant melanoma. Clin Cancer Res 1999; 5: 1961-1965 [PMID: 10473072]
48. 48 Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids––the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-477 [PMID: 21647195 DOI: 10.1038/nrclinonc.2011.76]
49. 49 Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn 2013; 13: 183-204 [PMID: 23477558 DOI: 10.1586/ erm.12.134]
50. 50 Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn 2013; 15: 827-834 [PMID: 23988620 DOI: 10.1016/j. jmoldx.2013.07.005]
51. 51 Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Bri- ant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518 [PMID: 18663219 DOI: 10.1073/ pnas.0804549105]
52. 52 Weber J A, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741 [PMID: 20847327 DOI: 10.1373/clinchem.2010.147405]
53. 53 Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs––the micro steering wheel of tumour metasta- ses. Nat Rev Cancer 2009; 9: 293-302 [PMID: 19262572 DOI: 10.1038/nrc2619]
54. 54 Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Charac¬terization of microRNAs in serum: a novel class of biomark¬ers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
55. 55 Shen J, Stass SA, Jiang F. MicroRNAs as potential biomark¬ers in human solid tumors. Cancer Lett 2013; 329: 125-136 [PMID: 23196059 DOI: 10.1016/j.canlet.2012.11.001]
56. 56 Coskun M, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease––pathogenesis, diagnostics and therapeutics. World J Gastroenterol 2012; 18: 4629-4634 [PMID: 23002331 DOI: 10.3748/wjg.v18.i34.4629]
57. 57 Ganepola GA, Mazziotta RM, Weeresinghe D, Corner GA, Parish CJ, Chang DH, Tebbutt NC, Murone C, Ahmed N, Augenlicht LH, Mariadason JM. Gene expression profiling of primary and metastatic colon cancers identifies a reduced pro¬liferative rate in metastatic tumors. Clin Exp Metastasis 2010; 27: 1-9 [PMID: 19882219 DOI: 10.1007/s10585-009-9295-2]
58. 58 Chang DH, Rutledge JR, Patel AA, Heerdt BG, Augenlicht LH, Korst RJ. The effect of lung cancer on cytokine expres¬sion in peripheral blood mononuclear cells. PLoS One 2013; 8: e64456 [PMID: 23762239 DOI: 10.1371/journal.pone.0064456]
59. 59 Quaglino P, Savoia P, Osella-Abate S, Bernengo MG. RT- PCR tyrosinase expression in the peripheral blood of mela¬noma patients. Expert Rev Mol Diagn 2004; 4: 727-741 [PMID: 15347265 DOI: 10.1586/14737159.4.5.727]
60. 60 Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastro¬enterol 2010; 16: 5965-5974 [PMID: 21157973]
61. 61 DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM, Cherrington JM. Expres¬sion profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003; 3: 3 [PMID: 12657164]
62. 62 Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME. Disease-associated ex¬pression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003; 63: 6069-6075 [PMID: 14522937]
63. 63 Marshall KW, Mohr S, Khettabi FE, Nossova N, Chao S, Bao W, Ma J, Li XJ, Liew CC. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 2010; 126: 1177-1186 [PMID: 19795455 DOI: 10.1002/ijc.24910]
64. 64 Yip KT, Das PK, Suria D, Lim CR, Ng GH, Liew CC. A case- controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res 2010; 29: 128 [PMID: 20846378 DOI: 10.1186/1756¬9966-29-128]
65. 65 Chao S, Ying J, Liew G, Marshall W, Liew CC, Burakoff R. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study. J Exp Clin Cancer Res 2013; 32: 44 [PMID: 23876008 DOI: 10.1186/1756-9966-32-44]
66. 66 Novak DJ, Liew GJ, Liew CC. GeneNews Limited: bringing the blood transcriptome to personalized medicine. Pharma- cogenomics 2012; 13: 381-385 [PMID: 22379995 DOI: 10.2217/ pgs.12.12]
67. 67 Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827-887 [PMID: 21742789 DOI: 10.1152/physrev.00006.2010]
68. 68 Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227 [PMID: 18817506 DOI: 10.1146/annurev. pathol.4.110807.092222]
69. 69 Krutovskikh VA, Herceg Z. Oncogenic microRNAs (On- comiRs) as a new class of cancer biomarkers. Bioessays 2010; 32: 894-904 [PMID: 21105295]
70. 70 Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000; 6: 3823-3826 [PMID: 11051224]
71. 71 Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011; 91: 579-587 [PMID: 21116241 DOI: 10.1038/labinvest.2010.194]
72. 72 Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with dif¬fuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675 [PMID: 18318758 DOI: 10.1111/j.1365-2141.2008.07077.x]
73. 73 Kulasingam V, Pavlou MP, Diamandis EP. Integrating high- throughput technologies in the quest for effective biomark¬ers for ovarian cancer. Nat Rev Cancer 2010; 10: 371-378 [PMID: 20383179 DOI: 10.1038/nrc2831]
74. 74 Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a bio¬marker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-618 [PMID: 22194634 DOI: 10.1373/ clinchem.2011.172767]
75. 75 Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol 2014; 6: 22-33 [PMID: 24578785 DOI: 10.4251/wjgo. v6.i1.22]
76. 76 Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381 [PMID: 19201770 DOI: 10.1136/gut.2008.167817]
77. 77 Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L, Huang D, Tan C, Sheng W, Du X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012; 7: e44398 [PMID: 22970209 DOI: 10.1371/ journal.pone.0044398]
78. 78 Giráldez MD, Lozano JJ, Ramírez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating microRNAs as biomark¬ers of colorectal cancer: results from a genome-wide profil¬ing and validation study. Clin Gastroenterol Hepatol 2013; 11: 681-8.e3 [PMID: 23267864 DOI: 10.1016/j.cgh.2012.12.009]
79. 79 Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 2013; S: e62880 [PMID: 23690963 DOI: 10.1371/journal.pone.0062880]
80. 80 Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A, Galan- diuk S. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorec¬tal cancer. Ann Surg 2013; 25S: 400-408 [PMID: 24022433 DOI: 10.1097/SLA.0b013e3182a15bcc]
81. 81 Ahmed FE, Amed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Allison RR. Di¬agnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 2012; 9: 179-192 [PMID: 22798503]
82. 82 Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detec¬tion of colorectal cancer. Int J Cancer 2010; 127: 118-126 [PMID: 19876917 DOI: 10.1002/ijc.25007]
83. 83 Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, Sun XF. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 2013; 34: 2175-2181 [PMID: 23625654 DOI: 10.1007/s13277-013-0753-8]
84. 84 Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Ji¬ang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-1680 [PMID: 20880178 DOI: 10.1111/j.1440-1746.2010.06417.x]
85. 85 Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012; 36: e61-e67 [PMID: 22018950 DOI: 10.1016/j.canep.2011.05.002]
86. 86 Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Cir¬culating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6: e17745 [PMID: 21445232 DOI: 10.1371/journal.pone.0017745]
87. 87 Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 2012; 13S: 1659-1666 [PMID: 22638884 DOI: 10.1007/s00432-012-1244-9]
88. 88 Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as bio¬markers in colorectal cancer. Cancer Biomark 2012; 12: 199-204 [PMID: 23568010 DOI: 10.3233/CBM-130308]
89. 89 Mardis ER. A decade's perspective on DNA sequencing technology. Nature 2011; 470: 198-203 [PMID: 21307932 DOI: 10.1038/nature09796]
90. 90 Human genome at ten: The sequence explosion. Nature 2010; 464: 670-671 [PMID: 20360711 DOI: 10.1038/464670a]
91. 91 Wetterstrand KA. DNA Sequencing Costts: Data from the NHGRI Genome Sequencing Program (GSP). Available from: URL: http: / / www.genome.gov/ sequencingcosts
92. 92 Peters BA, Kermani BG, Sparks AB, Alferov O, Hong P, Alexeev A, Jiang Y, Dahl F, Tang YT, Haas J, Robasky K, Zaranek AW, Lee JH, Ball MP, Peterson JE, Perazich H, Yeung G, Liu J, Chen L, Kennemer MI, Pothuraju K, Kon- vicka K, Tsoupko-Sitnikov M, Pant KP, Ebert JC, Nilsen GB, Baccash J, Halpern AL, Church GM, Drmanac R. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature 2012; 4S7: 190-195 [PMID: 22785314 DOI: 10.1038/nature11236]
93. 93 Su Z, Ning B, Fang H, Hong H, Perkins R, Tong W, Shi L. Next-generation sequencing and its applications in molecu¬lar diagnostics. Expert Rev Mol Diagn 2011; 11: 333-343 [PMID: 21463242 DOI: 10.1586/erm.11.3]
94. 94 Ozsolak F, Milos PM. RNA sequencing: advances, challeng¬es and opportunities. Nat Rev Genet 2011; 12: 87-98 [PMID: 21191423 DOI: 10.1038/nrg2934]
95. 95 Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387-402 [PMID: 18576944 DOI: 10.1146/annurev.genom.9.081307.164359]
96. 96 Sinicropi D, Qu K, Collin F, Crager M, Liu ML, Pelham RJ, Pho M, Dei Rossi A, Jeong J, Scott A, Ambannavar R, Zheng C, Mena R, Esteban J, Stephans J, Morlan J, Baker J. Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. PLoS One 2012; 7: e40092 [PMID: 22808097 DOI: 10.1371/ journal. pone.0040092]
97. 97 Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY. Identi¬fication of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing. Oncogene 2013; Epub ahead of print [PMID: 24141781 DOI: 10.1038/ onc.2013.424]
98. 98 Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Lu- iselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, Martinelli G. Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. Blood Cancer J 2012; 2: e61 [PMID: 22829256 DOI: 10.1038/bcj.2012.6]
99. 99 Xiao W, Tran B, Staudt LM, Schmitz R. High-throughput RNA sequencing in B-cell lymphomas. Methods Mol Biol 2013; 971: 295-312 [PMID: 23296971 DOI: 10.1007/978-1-6270 3-269-8_17]
100. 100 Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adi- conis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nus¬baum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Res 2010; 20: 413-427 [PMID: 20179022 DOI: 10.1101/gr.103697.109]
101. 101 Kunz M, Dannemann M, Kelso J. High-throughput sequenc¬ing of the melanoma genome. Exp Dermatol 2013; 22: 10-17 [PMID: 23174022 DOI: 10.1111/exd.12054]
102. 102 Cheng P, Cheng Y, Li Y, Zhao Z, Gao H, Li D, Li H, Zhang T. Comparison of the gene expression profiles between smok¬ers with and without lung cancer using RNA-Seq. Asian Pac J Cancer Prev 2012; 13: 3605-3609 [PMID: 23098441]
103. 103 Kalari KR, Rossell D, Necela BM, Asmann YW, Nair A, Ba- heti S, Kachergus JM, Younkin CS, Baker T, Carr JM, Tang X, Walsh MP, Chai HS, Sun Z, Hart SN, Leontovich AA, Hossain A, Kocher JP, Perez EA, Reisman DN, Fields AP, Thompson EA. Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Al¬ternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Muta¬tions. Front Oncol 2012; 2: 12 [PMID: 22655260 DOI: 10.3389/ fonc.2012.00012]
104. 104 Wu Y, Wang X, Wu F, Huang R, Xue F, Liang G, Tao M, Cai P, Huang Y. Transcriptome profling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One 2012; 7: e41001 [PMID: 22905095 DOI: 10.1371/journal.pone.0041001]
105. 105 Atkinson SR, Marguerat S, Bähler J. Exploring long non-cod¬ing RNAs through sequencing. Semin Cell Dev Biol 2012; 23: 200-205 [PMID: 22202731 DOI: 10.1016/j.semcdb.2011.12.003]
106. 106 Guenzl PM, Barlow DP. Macro lncRNAs: a new layer of cis- regulatory information in the mammalian genome. RNA Biol 2012; 9: 731-741 [PMID: 22617879 DOI: 10.4161/rna.19985]
107. 107 Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1: 391-407 [PMID: 22096659 DOI: 10.1158/2159-8290.CD-11-0209]
108. 108 Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Can¬cer Lett 2013; 339: 159-166 [PMID: 23791884 DOI: 10.1016/ j.canlet.2013.06.013]
109. 109 de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-2698 [PMID: 11980670]
110. 110 Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15; dis¬cussion 15-16 [PMID: 12814669]
111. 111 Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Can¬cer Lett 2011; 301: 1-6 [PMID: 21093148 DOI: 10.1016/j.can- let.2010.10.019]
112. 112 Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, Jia W. Overex¬pression of long noncoding RNA PCAT-1 is a novel bio¬marker of poor prognosis in patients with colorectal cancer. Med Oncol 2013; 30: 588 [PMID: 23640607 DOI: 10.1007/s120 32-013-0588-6]
113. 113 Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer 2013; 12: 261-266 [PMID: 24012455 DOI: 10.1016/j.clcc.2013.06.003]
114. 114 Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafa R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia- Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013; 23: 1446-1461 [PMID: 23796952 DOI: 10.1101/gr.152942.112]
115. 115 Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates poly¬comb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6326 [PMID: 21862635 DOI: 10.1158/0008-5472. CAN-11-1021]
116. 116 Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H. As¬sociation of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat 2012; 136: 875-883 [PMID: 23124417 DOI: 10.1007/s10549-012-2314-z]
117. 117 Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non¬coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 2011; 39: 169-175 [PMID: 21503572 DOI: 10.3892/ijo.2011.1007]
118. 118 Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650 [PMID: 837366]
119. 119 Choi JJ, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apop- totic and necrotic cells. Immunology 2005; 115: 55-62 [PMID: 15819697 DOI: 10.1111 /j.1365-2567.2005.02130.x]
120. 120 Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic ac¬ids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437 [PMID: 21562580 DOI: 10.1038/nrc3066]
121. 121 Kaiser J. Medicine. Keeping tabs on tumor DNA. Science 2010; 327: 1074 [PMID: 20185705 DOI: 10.1126/science.327.5969.1074]
122. 122 Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counter¬parts. Nature 1983; 301: 89-92 [PMID: 6185846]
123. 123 Sandoval J, Esteller M. Cancer epigenomics: beyond genom¬ics. Curr Opin Genet Dev 2012; 22: 50-55 [PMID: 22402447 DOI: 10.1016/j.gde.2012.02.008]
124. 124 Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428 [PMID: 12042769 DOI: 10.1038/nrg816]
125. 125 Gyparaki MT, Basdra EK, Papavassiliou AG. DNA meth- ylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl) 2013; 91: 1249-1256 [PMID: 24057814 DOI: 10.1007/s00109-013-1088-z]
126. 126 Goessl C, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, Miller K. Fluorescent methylation-specific poly¬merase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60: 5941-5945 [PMID: 11085508]
127. 127 Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer pa¬tients. Int J Cancer 2003; 105: 491-493 [PMID: 12712439 DOI: 10.1002/ijc.11117]
128. 128 Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P. Detec¬tion of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prog¬nosis. Int J Cancer 2002; 100: 542-548 [PMID: 12124803 DOI: 10.1002/ijc.10526]
129. 129 Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. De¬tection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon can¬cer. Cancer Res 2001; 61: 900-902 [PMID: 11221878]
130. 130 Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ. Quantitative detection of promoter hyper- methylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005; 100: 2274-2279 [PMID: 16181380 DOI: 10.1111/j.1572-0241.2005.50412.x]
131. 131 Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hy- permethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70 [PMID: 9892187]
132. 132 Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895 [PMID: 10706101]
133. 133 Domínguez G, Carballido J, Silva J, Silva JM, García JM, Menéndez J, Provencio M, España P, Bonilla F. p14ARF pro¬moter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002; 8: 980-985 [PMID: 11948103]
134. 134 Yin H, Liang Y, Yan Z, Liu B, Su Q. Mutation spectrum in human colorectal cancers and potential functional rel¬evance. BMC Med Genet 2013; 14: 32 [PMID: 23497483 DOI: 10.1186/1471-2350-14-32]
135. 135 Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark¬ers Prev 1994; 3: 67-71 [PMID: 8118388]
136. 136 Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994; 86: 774-779 [PMID: 7918071]
137. 137 Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, Mendy M, Friesen MD, Whittle H, Montesano R, Hainaut P. Ser-249TP53 mutation in tumour and plasma DNA of he¬patocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004; 110: 374-379 [PMID: 15095302 DOI: 10.1002/ijc.20103]
138. 138 Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of pa¬tients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102: 16368-16373 [PMID: 16258065 DOI: 10.1073/pnas.0507904102]
139. 139 Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-990 [PMID: 18670422 DOI: 10.1038/nm.1789]
140. 140 Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: prac¬tical aspects and biological significance. Mutat Res 2007; 635: 105-117 [PMID: 17257890 DOI: 10.1016/j.mrrev.2006.11.002]
141. 141 Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sid- ransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998; 58: 1405-1407 [PMID: 9537240]
142. 142 Ito S, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of tumor DNA in serum of colorectal cancer patients. Jpn J Cancer Res 2002; 93: 1266-1269 [PMID: 12460469]
143. 143 Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996; 2: 1033-1035 [PMID: 8782463]
144. 144 Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Mic¬rosatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-1037 [PMID: 8782464]
145. 145 He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markow¬itz SD, Velculescu VE, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. Heteroplasmic mitochondrial DNA muta¬tions in normal and tumour cells. Nature 2010; 464: 610-614 [PMID: 20200521 DOI: 10.1038/nature08802]
146. 146 Kuo SJ, Chen M, Ma GC, Chen ST, Chang SP, Lin WY, Chen YC, Lee TH, Lin TT, Liu CS. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation. Cancer Genet Cytogenet 2010; 201: 94-101 [PMID: 20682393 DOI: 10.1016/ j.cancergencyto.2010.05.013]
147. 147 Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. Detection of mitochon¬drial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 2001; 94: 429-431 [PMID: 11745425]
148. 148 Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009; 8: 105 [PMID: 19922604 DOI: 10.1186/1476-4598-8-105]
149. 149 Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate can¬cer. Clin Cancer Res 2007; 13: 421-426 [PMID: 17255261 DOI: 10.1158/1078-0432.CCR-06-1087]
150. 150 Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mi¬tochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 2008; 112: 843-850 [PMID: 18827127 DOI: 10.1097/AOG.0b013e3181867bc0]
151. 151 Takeuchi H, Fujimoto A, Hoon DS. Detection of mitochon¬drial DNA alterations in plasma of malignant melanoma patients. Ann N Y Acad Sci 2004; 1022: 50-54 [PMID: 15251939 DOI: 10.1196/annals.1318.009]
152. 152 Okochi O, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T, Nakao A. Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res 2002; 8: 2875-2878 [PMID: 12231530]
153. 153 Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B. Somatic muta¬tions of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20: 291-293 [PMID: 9806551 DOI: 10.1038/3108]
154. 154 Schaaij-Visser TB, de Wit M, Lam SW, Jiménez CR. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 2013; 1834: 2242-2258 [PMID: 23376433 DOI: 10.1016/ j.bbapap.2013.01.029]
155. 155 Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Go- edert JJ, Mendy M, Hollstein MC, Montesano R, Groopman JD, Hainaut P, Friesen MD. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 2005; 14: 2956-2962 [PMID: 16365016 DOI: 10.1158/1055-9965. EPI-05-0612]
156. 156 Taguchi A, Hanash SM. Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem 2013; 59: 119-126 [PMID: 23099557 DOI: 10.1373/clinchem.2012.184572]
157. 157 Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy con¬trols using surface-enhanced laser desorption ionisation¬time of flight mass spectrometry. World J Gastroenterol 2006; 12: 1536-1544 [PMID: 16570345]
158. 158 Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walk¬er JJ, Weissfeld JL, Williams S, Zichi D, Brody EN. Unlocking biomarker discovery: large scale application of aptamer pro- teomic technology for early detection of lung cancer. PLoS One 2010; 5: e15003 [PMID: 21170350 DOI: 10.1371/journal. pone.0015003]
159. 159 de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013; 46: 466-479 [PMID: 23159294 DOI: 10.1016/j.clinbioche m.2012.10.039]
160. 160 Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-551 [PMID: 22868372 DOI: 10.1097/SLA.0b013e318265bd6f]
161. 161 Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105: 849-859 [PMID: 23704278 DOI: 10.1093/jnci/djt101]
162. 162 Menéndez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menéndez JM, Rodríguez-Montes JA. Prognostic implica¬tions of serum microRNA-21 in colorectal cancer. J Surg Oncol 2013; 108: 369-373 [PMID: 23970420 DOI: 10.1002/ jso.23415]
163. 163 Huang Y, Yang YB, Zhang XH, Yu XL, Wang ZB, Cheng XC. MicroRNA-21 gene and cancer. Med Oncol 2013; 30: 376 [PMID: 23277281 DOI: 10.1007/s12032-012-0376-8]
164. 164 Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancre¬atic and colorectal adenocarcinoma. Int J Cancer 2013; 132: E48-E57 [PMID: 22907602 DOI: 10.1002/ijc.27791]
165. 165 Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 659-669 [PMID: 18838717]
166. 166 Rockey DC, Paulson E, Niedzwiecki D, Davis W, Bosworth HB, Sanders L, Yee J, Henderson J, Hatten P, Burdick S, Sanyal A, Rubin DT, Sterling M, Akerkar G, Bhutani MS, Binmoeller K, Garvie J, Bini EJ, McQuaid K, Foster WL, Thompson WM, Dachman A, Halvorsen R. Analysis of air contrast barium enema, computed tomographic colonogra- phy, and colonoscopy: prospective comparison. Lancet 2005; 365: 305-311 [PMID: 15664225 DOI: 10.1016/S0140-6736(05)1 7784-8]